Taken together, our results provide a proof-of-principle and preclinical evidence that MAT2A inhibition leads to anti-leukemic effects in MLLr leukemia and can easily be combined with other targeted therapies or chemotherapy to overcome the poor prognosis in MLLr leukemia. This evidence concerns the gene MAT2A and leukemia.